Literature DB >> 16850346

Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells.

Il-Kang Na1, Ulrich Keilholz, Anne Letsch, Sandra Bauer, Anne Marie Asemissen, Dirk Nagorsen, Eckhard Thiel, Carmen Scheibenbogen.   

Abstract

T-cell trafficking is determined by expression patterns of chemokine receptors. The chemokine receptor CXCR3 is expressed on a subpopulation of type 1 T cells and plays an important role for migration of T cells into inflamed and tumor tissues. Here, we studied the chemokine receptor expression on specific T cells generated against the neoantigen keyhole limpet hemocyanin (KLH) in patients who had been immunized in the context of a tumor peptide vaccination trial with or without the adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF). In patients immunized in the presence of GM-CSF the fraction of CXCR3(+) KLH-specific T cells was significantly higher than in patients immunized in the absence of GM-CSF (median 45 vs. 20%, P = 0.001). In contrast, the chemokine receptor CCR4, associated with migration to the skin was found in both cohorts on less than 10% of KLH-specific T cells. These results show that CXCR3 expression on vaccine-induced T cells can be modulated by modifying the local vaccine milieu.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16850346     DOI: 10.1007/s00262-006-0198-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

Review 1.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.

Authors:  Craig L Slingluff; Gina R Petroni; Walter C Olson; Mark E Smolkin; Merrick I Ross; Naomi B Haas; William W Grosh; Marc E Boisvert; John M Kirkwood; Kimberly A Chianese-Bullock
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

3.  Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.

Authors:  Eleanor Clancy-Thompson; Laura K King; Lenora D Nunnley; Irene M Mullins; Craig L Slingluff; David W Mullins
Journal:  Cancer Immunol Res       Date:  2013-11       Impact factor: 11.151

4.  Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment.

Authors:  Wan-Lun Yan; Chiao-Chieh Wu; Kuan-Yin Shen; Shih-Jen Liu
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

Review 5.  Update on vaccine development for renal cell cancer.

Authors:  Nina Chi; Jodi K Maranchie; Leonard J Appleman; Walter J Storkus
Journal:  Open Access J Urol       Date:  2010-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.